While it is true that we are still waiting for the final results of important clinical trials with reparative intention in patients with ST-segment elevation acute myocardial infarction, it appears clear that new regenerative and/or reparative products warrant further investigations. This is the case of this manuscript, which demonstrates that the manipulation of induced-pluripotent stem cell-derived cardiomyocytes to overexpress N-cadherin may improve the effectiveness of the cells in a murine model, in terms of cellular engraftment, left ventricular ejection fraction and infract size. The authors also further expand our mechanistic knowledge by identifying a cellular pathway (ERK) that appears to be linked to the higher survival of implanted cells and to the higher neo-vasculogenic capacity of the treatment.
Our mission: To reduce the burden of cardiovascular disease.